National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2018 (No. 3) (PB 21 of 2018) (Cth)

PB 21 of 2017

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2017 (No. 3)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated         26^th of March 2018

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

___________________________________________________________________________

Amendment instrument – Pharmaceutical benefits – early supply

1          Name of Instrument

(1)      This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2018 (No. 3)

(2)This Instrument may also be cited as PB 21 of 2018.

2          Commencement

This Instrument commences on 1 April 2018.

3          Amendment of PB 120 of 2015

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

Schedule 1        Amendments

1. Schedule 1, after entry for Certolizumab pegol

insert:

Certolizumab pegol Solution for injection 200 mg in 1 mL pre-filled pen 20 2 5

1. Schedule 1, after entry for Empagliflozin in the form Tablet 25 mg

insert:

Empagliflozin with linagliptin	Tablet containing 10 mg empagliflozin with 5 mg linagliptin	20	30	5
Empagliflozin with linagliptin	Tablet containing 25 mg empagliflozin with 5 mg linagliptin	20	30	5

1. Schedule 1, after entry for Metformin with glibenclamide in the form Tablet containing metformin hydrochloride 500 mg with glibenclamide 5 mg

insert:

Methotrexate	Injection 7.5 mg in 0.15 mL pre-filled syringe	20	4	5
Methotrexate	Injection 10 mg in 0.2 mL pre-filled syringe	20	4	5
Methotrexate	Injection 15 mg in 0.3 mL pre-filled syringe	20	4	5
Methotrexate	Injection 20 mg in 0.4 mL pre-filled syringe	20	4	5
Methotrexate	Injection 25 mg in 0.5 mL pre-filled syringe	20	4	5

1. Schedule 1, after entry for Saxagliptin in the form Tablet 5 mg (as hydrochloride)

insert:

Saxagliptin with dapagliflozin Tablet containing saxagliptin 5 mg with dapaglifozin 10 mg 20 28 5

1. Schedule 1, after entry for Sofosbuvir in the form Tablet 400 mg [Maximum Quantity: 28; Number of Repeats: 5]

insert:

Sonidegib Capsule 200 mg 20 30 3

1. Schedule 1, after entry for Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat

insert:

Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 291 mg with emtricitabine 200 mg	20	30	2
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	20	30	2
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg	20	30	2